See more : JOFF Fintech Acquisition Corp. (JOFFU) Income Statement Analysis – Financial Results
Complete financial analysis of RIV Capital Inc. (CNPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RIV Capital Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Noble Roman’s, Inc. (NROM) Income Statement Analysis – Financial Results
- Shenzhen Expressway Corporation Limited (SHZNF) Income Statement Analysis – Financial Results
- Bouygues SA (BOUYF) Income Statement Analysis – Financial Results
- AViC Co., Ltd. (9554.T) Income Statement Analysis – Financial Results
- Icape Holding S.A. (ALICA.PA) Income Statement Analysis – Financial Results
RIV Capital Inc. (CNPOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rivcapital.com
About RIV Capital Inc.
RIV Capital Inc., formerly known as Canopy Rivers Inc., is a venture capital firm. The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds. It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content. The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals. In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science. In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation. In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services. In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment. In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories. In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others. The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to $40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was founded on 2017 and is based in Toronto, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 5.64M | 6.81M | 1.43M | 10.10M | 8.13M | 3.16M | 70.64M |
Cost of Revenue | 6.36M | 4.37M | 0.00 | 53.63M | -4.06M | -1.70M | 0.00 |
Gross Profit | -721.51K | 2.44M | 1.43M | -43.53M | 12.18M | 4.87M | 70.64M |
Gross Profit Ratio | -12.80% | 35.77% | 100.00% | -431.09% | 149.90% | 153.77% | 100.00% |
Research & Development | -10.73 | 0.00 | -21.19 | -8.52 | -2.83 | 2.15 | 0.00 |
General & Administrative | 0.00 | 17.97M | 7.76M | 6.09M | 13.02M | 22.32M | 2.41M |
Selling & Marketing | 0.00 | 351.00K | 0.00 | 0.00 | 0.00 | 560.89K | 7.86M |
SG&A | -8.66 | 20.50M | 7.76M | 6.09M | 13.02M | 22.32M | 10.28M |
Other Expenses | -63.77M | 1.22M | 561.96K | -1.13M | 969.69K | 236.62K | 1.29 |
Operating Expenses | 15.89M | 20.83M | 10.44M | 81.04M | 13.33M | 22.28M | 10.28M |
Cost & Expenses | 22.25M | 25.20M | 10.44M | 81.04M | 13.33M | 22.28M | -10.28M |
Interest Income | 0.00 | 653.00K | 1.51M | 12.75M | 4.86M | 1.63M | 0.00 |
Interest Expense | 11.09M | 17.22M | 5.78M | 22.17K | 25.37K | 0.00 | 81.60K |
Depreciation & Amortization | 22.25M | 2.00M | 58.01M | 37.79M | 36.81M | -5.32M | 43.82K |
EBITDA | -15.27M | -16.04M | -9.56M | -101.94M | -8.45M | -20.50M | -163.21K |
EBITDA Ratio | -270.84% | -235.70% | -670.26% | -1,009.54% | -103.95% | -647.80% | -0.23% |
Operating Income | 1.34M | -22.85M | -48.80M | -119.12M | -29.57M | 6.01M | 60.36M |
Operating Income Ratio | 23.77% | -335.63% | -3,421.16% | -1,179.66% | -363.77% | 189.94% | 85.45% |
Total Other Income/Expenses | 102.29M | -147.21M | -37.40M | -49.67M | -23.40M | 25.36M | -81.60K |
Income Before Tax | -15.27M | -182.18M | -52.20M | -120.63M | -28.62M | 6.25M | -43.82K |
Income Before Tax Ratio | -270.84% | -2,676.29% | -3,659.04% | -1,194.65% | -352.15% | 197.42% | -0.06% |
Income Tax Expense | -16.61M | -2.92M | -9.98M | -14.63M | -35.94K | 3.31M | -43.82K |
Net Income | -80.38M | -179.26M | -42.21M | -106.01M | -28.59M | 2.93M | -43.82K |
Net Income Ratio | -1,425.74% | -2,633.45% | -2,959.09% | -1,049.79% | -351.71% | 92.71% | -0.06% |
EPS | 126.73M | -1.09 | -0.30 | -0.75 | -0.15 | 0.02 | 0.00 |
EPS Diluted | 126.73M | -1.09 | -0.30 | -0.75 | -0.15 | 0.02 | 0.00 |
Weighted Avg Shares Out | -0.63 | 164.12M | 142.42M | 142.08M | 188.37M | 167.02M | 99.95M |
Weighted Avg Shares Out (Dil) | -0.63 | 164.12M | 142.42M | 142.08M | 188.37M | 167.02M | 99.95M |
RIV Capital Announces Shareholder Approval of Business Combination with Cansortium and Cansortium Announces Shareholder Approval of the Amendment Proposal
RIV Capital sets date for financial results for second quarter ended June 30, 2024
RIV Capital and Cansortium Inc. Provide Integration Update Ahead of Completing Merger
RIV Capital Strengthens Senior Leadership Team Ahead of Anticipated Transformational Merger with Cansortium Inc.
RIV Capital Reports Financial Results for the First Quarter Ended March 31, 2024
RIV Capital Applauds Reports that DEA Plans to Reschedule Cannabis
RIV Capital Inc. (CNPOF) Q4 2024 Earnings Call Transcript
RIV Capital Reports Financial Results for the Fiscal Quarter and Nine-Month Transition Period Ended December 31, 2023
RIV Capital Sets Date for Financial Results for the Fiscal Quarter and Nine-Month Transition Year Ended December 31, 2023
RIV Capital and Etain Open First New York Adult-Use Dispensary in White Plains
Source: https://incomestatements.info
Category: Stock Reports